Recruiting
Phase 2

Safusidenib

Sponsor:

Nuvation Bio Inc.

Code:

NCT05303519

Conditions

Glioma

Astrocytoma, Grade IV

IDH1-mutant Glioma

Astrocytoma, IDH-Mutant, Grade 3

Astrocytoma, IDH-Mutant, Grade 4

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

safusidenib

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-07. This information was provided to ClinicalTrials.gov by Nuvation Bio Inc. on 2025-10-29.